National indication protocol for proton radiotherapy in esophageal cancer patients in the Netherlands.
Christina T Muijs, Yvonne L B Klaver, Joost Nuyttens...
https://pubmed.ncbi.nlm.nih.gov/41005671/Actively Recruiting
Led by University of Aarhus · Updated on 2024-12-17
396
Participants Needed
15
Research Sites
261 weeks
Total Duration
Researchers are evaluating whether proton therapy PT can reduce treatment-related lung complications compared to standard photon therapy XT in patients with operable esophageal or gastro-esophageal junction cancer. This international, multicenter, phase III study compares neoadjuvant chemoradiotherapy using either photons or protons, aiming to improve outcomes by reducing damage to healthy tissues during radiation treatment. Participants receive neoadjuvant chemoradiotherapy with weekly carboplatin and paclitaxel for five cycles, combined with either photon or proton radiotherapy. Radiation doses are either 41.4 Gy in 23 fractions or 50.4 Gy in 28 fractions, given five days per week. Patients are randomly assigned to either the photon or proton therapy group, with treatment regimens standardized across centers. Surgery follows the chemoradiotherapy, with planned transthoracic esophagectomy or gastrectomy. During the study, patients undergo regular evaluations including imaging FDG PETCT, laboratory tests, and assessments of lung and cardiovascular health. Researchers monitor for lung complications from randomization until 90 days after surgery, as well as other outcomes like early and late toxicity, complications, cardiovascular events, treatment compliance, and survival over up to five years. The study involves careful follow-up to assess the safety and effects of each treatment approach.
CONDITIONS
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
D
Dorte Winter
T
Toke Hansen, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Aarhus
Lead Sponsor
University of Leeds
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 weeks
Participants receive neoadjuvant chemoradiotherapy with either proton or photon radiation combined with weekly chemotherapy for 5 weeks before surgery.
Weekly visits for 5 weeks
Duration - Up to 90 days after surgery
Participants undergo planned transthoracic esophagectomy or gastrectomy followed by immediate post-operative care.
Approximately 6 post-operative visits
Duration - Up to 5 years
Participants are monitored for long-term outcomes including toxicity, complications, cardiovascular events, patient-reported outcomes, and survival for up to 5 years after surgery.
Periodic follow-up visits over 5 years
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Christina T Muijs, Yvonne L B Klaver, Joost Nuyttens...
https://pubmed.ncbi.nlm.nih.gov/41005671/University of Aarhus
Lead Sponsor
University of Leeds
Collaborating Sponsor